Physiologic coagulation proteins

Physiologic coagulation proteins, commonly referred to as clotting factors, are a group of plasma proteins that play a critical role in the hemostatic system by regulating blood clot formation [1]. These proteins typically circulate as inactive zymogens and are activated through a sequential cascade involving the intrinsic, extrinsic, and common pathways, ultimately leading to the conversion of fibrinogen into a stable fibrin mesh [1][2]. Most of these factors, such as Factor II (thrombin), VII, IX, and X, are serine proteases, while others like Factor V and VIII act as essential cofactors [2][3]. Deficiencies or mutations in these proteins can result in bleeding diatheses, such as Hemophilia A and B, while overactivity or impaired regulation can lead to pathological thrombosis, including deep vein thrombosis and stroke [1][4]. Because of their central role in vascular patency, these proteins are the primary targets for a wide range of pharmacological agents, including anticoagulants like warfarin and direct oral anticoagulants (DOACs), which are used to prevent and treat thromboembolic diseases [3][5]. Monitoring of these proteins is often performed using laboratory assays like prothrombin time and activated partial thromboplastin time to ensure therapeutic efficacy and safety [1][2]. Therapeutic intervention often requires a delicate balance between preventing thrombosis and avoiding life-threatening hemorrhage [5]. Sources: [1] StatPearls: Physiology, Coagulation Cascade (https://www.ncbi.nlm.nih.gov/books/NBK482256/); [2] Merck Manual: Overview of Hemostasis (https://www.merckmanuals.com/professional/hematology-and-oncology/hemostasis/overview-of-hemostasis); [3] PubMed: The coagulation cascade (https://pubmed.ncbi.nlm.nih.gov/15213108/); [4] NIH: Hemophilia (https://www.nhlbi.nih.gov/health/hemophilia); [5] PubMed: Pharmacology of Antithrombotic Drugs (https://pubmed.ncbi.nlm.nih.gov/21903477/).

Other names

Coagulation factorsClotting factorsBlood coagulation factorsHemostatic proteinsZymogens of the coagulation cascade

Drugs targeting these proteins function by inhibiting specific enzymatic activities (e.g., direct thrombin or Factor Xa inhibition), depleting functional levels of vitamin K-dependent factors, or accelerating the natural inhibitory action of antithrombin III to prevent or dissolve blood clots [3][5].